ACADIA Pharmaceuticals Inc has a consensus price target of $27.71, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Cantor Fitzgerald ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...

ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Issuing a $9 price target on the stock, Piper argued that TSHA-102 ... In March, the U.S. approved Acadia Pharmaceuticals (ACAD) Rett syndrome therapy Daybue for those two years and older.

This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term ...